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OBJECTIVES: A model assessing sequential olfactory testing and dopamine trans-
porter (DAT) imaging for screening pre-motor Parkinson’s Disease (PD) was
adapted to a European setting with German cost and health utility data.METHODS:
PD Associated Risk Study (PARS) data were used to parameterize screening efficacy.
Screening strategies in persons 1) in a general population, 2) with a relative with PD,
3) with LRRK2 genotype, and 4) with REM sleep disorder were evaluated. PD prev-
alence per 100 at screening was 0.5, 2, 10 and 20 for these groups. Olfactory test and
DAT costs were €11 and €1500, respectively. We assumed disease modifying (DM)
therapy was available that slowed disease progression by 20% at a cost of €30,000.
Economic value was measured in net monetary benefits (NMB), valuing a quality-
adjusted life-year at €50,000. RESULTS: Screening sensitivity and specificity were
64% and 99%, respectively. 13.4% had positive results on the olfactory test and also
took the DAT. NMB for the four groups was €-169, €269, €2,603, and €5,521, indicat-
ing that screening has positive economic value in persons with a close relative with
PD, persons with LRRK2 genotype, and persons with REM sleep disorder. Screen-
ing value was positively correlated with rate of progression from preclinical to
clinical PD, efficacy of DM therapy, and QALY monetization. Screening value was
negatively correlated with costs of false positives, screening cost, age at onset,
Hoehn and Yahr stage at which the unscreened diagnosis is made, and cost of DM
therapy. CONCLUSIONS: Screening for early PD may be a cost-effective strategy for
certain risk groups.
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OBJECTIVES: New diagnostic approaches, including molecular profiling, have im-
proved the ability to establish accurate diagnoses of hematologic cancers, but have
also increased the complexity of test ordering, information integration and inter-
pretation. This study examined the role of specialty and other laboratory providers,
the types of diagnostic tests provided for patients with suspected hematologic
cancers, and subsequent health care costs. METHODS: Patients with bone marrow
biopsies and suspected hematologic cancer/condition (2005-2011) were identified
from claims data from a large US health plan. Included patients had 6 pre- &
3-months post-biopsy health plan coverage. Lab tests in the 30 days post-biopsy
were identified. Patient cohorts were based upon laboratories performing marrow
morphologic assessment/directing testing sequence: Genoptix (GX, a specialty he-
matology-testing laboratory); large commercial laboratories (LL), other laboratories
(OL); academic labs were excluded. Diagnostic/treatment medical costs (per-pa-
tient-per-month) during the 30-days & 1 year post-biopsy were examined (ANOVA).
RESULTS: Of 30,393 patients with suspected hematologic malignancy/condition,
94.25% had marrow morphology reviewed. OL patients were slightly younger (58.19
OL vs. , 59.88 GX, 59.39 LL, P0.001). More flow cytometry was done at GX (96.68%)
vs 87.68% in LL and 69.78% in OL. Cytogenetics/FISH analysis rates were: 95.96% GX,
80.78% LL, 51.68% OL. Use of molecular diagnostics was less common (26.03% in GX,
14.27% in LL and 9.31% in OL). 1-year PPPM costs were $4487 GX, $4325 LL, and $5407
OL (P0.001)); costs PPPM excluding the testing period were $2132 GX, $2686 LL, and
$3341 OL (P0.001). CONCLUSIONS: Frequency of diagnostic tests in the 30-days
post-biopsy varied, with complex tests conducted more frequently in the hematol-
ogy specialty laboratory. However, disease-related costs with the specialty labora-
tory were lower than costs for some laboratories with lower use of these tests.
Further exploration of the impact of alternative diagnostic testing approaches on
costs and clinical outcomes is warranted.
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OBJECTIVES: Due to high cost and limited availability of dual-energy x-ray absorp-
tiometry (DXA), 77 percent of high risk population remains undiagnosed and there-
fore untreated for osteoporosis. To cope up with current scenario, pre-screening
tools have become apparent as pragmatic tool for extensive screening of osteopo-
rosis. Use of such tools would help health care professionals to make better use of
bone densitometry and to cut billions of dollars cost associated with DXA. This
study attempts to evaluate possible reasons that pose hindrance in implementa-
tion of such tools despite of reliability and cost effective nature of such tools.
METHODS: Using convenience sampling method, a pre-validated questionnaire
was used to conduct a cross-sectional survey among health care professionals in
Malaysia. 5 endocrinologists, 10 orthopedic specialists, 25 medical officers, 30 hos-
pital pharmacists participated from Hospital Pulau Penang while 33 community
pharmacists and 27 general practitioners from Penang participated in survey(total
130). RESULTS: There was no statistically significant difference regarding knowl-
edge of pre-screening tools among health care professionals belonging to different
specialties. Although, 77% of participants have heard about pre-screening tools but
only 53 % were able to identify the purpose of such tools. Out of list of 8 pre-
screening tools, majority 36 % identified SCORE followed by MOST (22 %) as pre-
screening tools while other tools were not identified. Only 5 % of participants have
used such tools while 94 % showed willingness to use such tools and to encourage
patients to undergo screening by such tools. Majority 61 % preferred leaflets/ bro-
chures to gain information regarding availability and utility of such tools while
least 13 % preferred continuous education programs. CONCLUSIONS: Proper
awareness regarding availability and utility of such tools would not only help to
improve patient’s quality of life also it would help to reduce global economic bur-
den associated with osteoporosis.
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OBJECTIVES: Few data exists on high cardiovascular risk (HCVR) prevalence within
a primary prevention population. The goal of the study was to assess HCVR distri-
bution, according to the European SCORE risk assessment scale, in France in high-
risk primary care patients not treated with lipid-lowering drug. METHODS: This
observational study was conducted over a week on a representative sample of
French general practitioners (GP). All consulting primary care men/women 50/60
y, with at least one other CVR factor (smoking, high blood pressure (HBP), type 2
diabetes, HDL-c0.40 g/L), not treated for dyslipidemia were included in the study.
GP filled-in an on line questionnaire that enabled SCORE calculation. RESULTS:GPs
(n1147) included 9049 patients (mean age: 68 y; male: 57%; LDLc1.3 g/L: 57%;
smoking: 21%; HBP: 44%; type 2 diabetes: 21% HDL-c0.4 g/L: 16%). According to
SCORE, HCVR prevalence reached 50% in total population (male: 49%, female: 51%).
50% of HCVR men/women were older than 72.4/78.8 y. HCVR patients were older
by 7.7/6.8 y for male/female (p 0.01) than non-HCVR patients. Other significantly
more frequent characteristics in high CVR population are: HDL0.6 g/L (38%), un-
treated or uncontrolled HBP (53%) and left ventricular hypertrophy (8%). Obesity is
less frequent (15%) in high CVR population. Highest HCVR prevalence was observed
in the Mediterranean population (54%), and lowest (47%) in the Northeast popula-
tion (p 0.01). Adjustment by age and gender reduces regional disparities (52% vs
48%).CONCLUSIONS:Half consulting primary care patients aged50/60 y for men/
women with at least 1 risk factor on top of age and no lipid-lowering treatment are
at HCVR according to SCORE risk equation. Assessing cardiovascular risk with risk
equations appears particularly useful in this group of patients. Besides age, which
has the strongest impact on risk estimation, other RF may be screened to improve
HCVR management.
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OBJECTIVES: To systematically review the current clinical and cost-effectiveness
literature of third-generation, implantable left ventricular assist devices (LVADs)
for people with end-stage heart failure (ESHF). METHODS: Three implantable,
third-generation LVADs were identified as available in the EU. A systematic litera-
ture review was conducted of published and unpublished cost-effectiveness and
clinical data (comparative studies) in the ESHF population, since their inception till
April 2012, using a number of medical databases. RESULTS:One relevant economic
evaluation and four comparative clinical studies (1 vs. virtual control arm & 3 vs.
older-generation LVADs) met the inclusion criteria. Therapy success defined as
survival LVAD or explant to receive a heart transplant or for recovery, occurred in
approx. 92.0% of patients with third-generation LVADs and 90.1% of control pa-
tients (second-generation LVAD) in a 6-months period. The 1-year survival of pa-
tients who were implanted with third-generation LVADs ranged from 82% to 91%.
The most frequently reported adverse events were arrhythmias, bleeding, infec-
tion, respiratory and renal failure, right heart failure, and stroke. One included
study evaluates the cost-effectiveness of the implantable, third-generation LVADs
as destination therapy for patients with ESHF as compared to patients on medical
management in the UK. Results showed that at 5ys LVADs had an additional cost of
about £20,500 per patient and QALY gain of 1.05, giving an incremental cost per
QALY of £19 500, which is below the commonly adopted threshold of £25,000 per
QALY. However, this finding seems unreliable due to controversial assumptions.
CONCLUSIONS:Despite the poor methodological quality of included studies, third-
generation of implantable LVADs seems beneficial due to improving survival, ther-
apy success and functional status. Adverse events serious concern. No prospective
controlled data are available as bridge to recovery, nor destination therapy. There
is an urgent need for additional, reliable cost-effectiveness studies evaluating
third-generation pumps versus previous generations of LVADs.
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OBJECTIVES: To assess the clinical effectiveness of extracorporeal photopheresis
(ECP) in the treatment of acute or chronic steroid-refractory graft versus host dis-
ease (GvHD). METHODS: Clinical effectiveness of the analysed intervention was
evaluated in accordance with the principles of systematic review based on the
Cochrane Collaboration guidelines (Cochrane Reviewer’s Handbook) and the guide-
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